Other
13 Authors
- Chen D,
- Van Hook K,
- Sears R,
- Zhu Z,
- Spellman P,
- Wang Z,
- Sheppard B,
- Lee HJ,
- Nold C,
- Anur P,
- Yu Z,
- Dai MS,
- Lopez CD
| First Author | Van Hook K | Year | 2017 |
| Journal | Biochem Biophys Res Commun | Volume | 482 |
| Issue | 4 | Pages | 1271-1277 |
| PubMed ID | 27939881 | Mgi Jnum | J:241720 |
| Mgi Id | MGI:5903547 | Doi | 10.1016/j.bbrc.2016.12.027 |
| Citation | Van Hook K, et al. (2017) DeltaN-ASPP2, a novel isoform of the ASPP2 tumor suppressor, promotes cellular survival. Biochem Biophys Res Commun 482(4):1271-1277 |
| abstractText | ASPP2 is a tumor suppressor that works, at least in part, through enhancing p53-dependent apoptosis. We now describe a new ASPP2 isoform, DeltaN-ASPP2, generated from an internal transcription start site that encodes an N-terminally truncated protein missing a predicted 254 amino acids. DeltaN-ASPP2 suppresses p53 target gene transactivation, promoter occupancy, and endogenous p53 target gene expression in response to DNA damage. Moreover, DeltaN-ASPP2 promotes progression through the cell cycle, as well as resistance to genotoxic stress-induced growth inhibition and apoptosis. Additionally, we found that DeltaN-ASPP2 expression is increased in human breast tumors as compared to adjacent normal breast tissue; in contrast, ASPP2 is suppressed in the majority of these breast tumors. Together, our results provide insight into how this new ASPP2 isoform may play a role in regulating the ASPP2-p53 axis. |
